FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  10 11 12 13 14 15 16 17 18 19 20
 
TXT Enforcement Guide on Fecal Microbiota for Transplantation
11/28/2022
 
 
TXT No REMS Needed for Gene Therapy: FDA
11/28/2022
 
 
TXT Device Color Additive Risk Calculator Qualified
11/28/2022
 
 
TXT 2nd Alzheimer’s Therapy Death Raises Questions: Journal
11/28/2022
 
 
TXT Luer-Activated Valve Connector FDA Alert
11/23/2022
 
 
TXT Janssen Says Spravato Tops Seroquel in Trial
11/23/2022
 
 
TXT EUA for Lucira Covid-19 and Flu Test
11/23/2022
 
 
TXT FDA Waives Panel Meeting on Biomarin Gene Therapy
11/23/2022
 
 
TXT Controversy Seen in CDS Software Final Guidance
11/22/2022
 
 
TXT Alert on Prolia and Severe Hypocalcemia
11/22/2022
 
 
TXT FDA Modeling, Simulation Successes
11/22/2022
 
 
TXT GSK Pulls Blenrep Accelerated Approval at FDA’s Request
11/22/2022
 
 
TXT New Hemophilia B Gene Therapy Approved
11/22/2022
 
 
TXT Multiple Violations at Invitrx Therapeutics
11/22/2022
 
 
TXT Latest Philips Respironics MDRs
11/22/2022
 
 
TXT Webinar on Rx Drug Labeling Resources
11/21/2022
 
 
TXT FDA Updates Web Page on Medtronic HeartWare Recalls
11/21/2022
 
 
TXT Zimmer Biomet New Persoa Tibis Cleared
11/21/2022
 
 
TXT FDA OKs Jazz sBLA for Mon./Wed./Fri. Rylaze Dosing
11/21/2022
 
 
TXT Gamida Cell BLA Review Extended by 3 Months
11/21/2022
 
 
TXT Provention Bio Diabetes Delayer Approved
11/18/2022
 
 
TXT Inspections Focusing on Management Responsibility: FDA
11/18/2022
 
 
TXT Pfizer/BioNTech on ‘Encouraging’ Covid Booster Data
11/18/2022
 
 
TXT Iovance Pushes Back BLA for Melanoma Therapy
11/18/2022
 
 
TXT Bernie Sanders to Head HELP Committee
11/18/2022
 
 
TXT Philips Respironics Reports More Problems with Ventilators
11/18/2022
 
 
TXT Comments Sought on Proposed NDC Revision
11/17/2022
 
 
TXT FDA Warns 7 Supplement Companies About CV Claims
11/17/2022
 
 
TXT FDA Approves Lilly Interchangeable Insulin Product
11/17/2022
 
 
TXT 9 Senators Want FDA Medication Abortion Action
11/17/2022
 
 
TXT Advisors Back Ardelyx’ Kidney Disease Drug
11/17/2022
 
 
TXT Pazdur Puts Foot Down on Single Country Trials
11/17/2022
 
 
TXT FDA Planning White Oak Return Under Hybrid Approach
11/17/2022
 
 
TXT Class 1 Recall on Omnipod Insulin Delivery System
11/17/2022
 
 
TXT FDA Cybersecurity Modernization Action Plan
11/17/2022
 
 
TXT FDA Preliminary Assessment on OTC Naloxone
11/16/2022
 
 
TXT ‘Put Aduhelm Approval on Hold’: Researchers
11/16/2022
 
 
TXT CA Appeals Court Upholds Federal Preemption
11/16/2022
 
 
TXT FDA Denies 2 Covid-19 Vaccine Petitions
11/16/2022
 
 
TXT Takeaways from Clinical Trial Enforcement Panel
11/16/2022
 
 
TXT NEST Unique Device Identifier Playbook
11/16/2022
 
 
TXT Pass PASTEUR Act Before Congress Ends: 165 Groups
11/16/2022
 
 
TXT FDA Updates Cybersecurity Playbook
11/15/2022
 
 
TXT Certain Naloxone Products Could be OTC: FDA
11/15/2022
 
 
TXT FDA Questions Ardelyx’ Tenapanor
11/15/2022
 
 
TXT Workshop on Using Consensus Standards in Device Submissions
11/15/2022
 
 
TXT 1 Observation on Athenex Pharma FDA-483
11/15/2022
 
 
TXT Comments on Computer Software Assurance Guidance
11/15/2022
 
 
TXT Warning Letter ‘Top 10’ GMP Deficiencies
11/15/2022
 
 
TXT FDA Clears Surgical Augmented Reality Software
11/14/2022
 
 
TXT Protalix, Chiesi Resubmit Fabry Disease BLA
11/14/2022
 
 
TXT Roche Alzheimer’s Drug Misses in 2 Phase 3 Studies
11/14/2022
 
 
TXT Satsuma Plans Migraine NDA After Data Miss
11/14/2022
 
 
TXT ImmunoGen’s Elahere OK’d for Several Cancers
11/14/2022
 
 
TXT Insulet Device Correction on ‘Melting’ Omnipod 5
11/14/2022
 
 
TXT Regulatory Review Period for Merck’s Prevymis
11/11/2022
 
 
TXT GSK Narrows Zejula Indication at FDA’s Request
11/11/2022
 
 
TXT FTC Takes Issue with Jazz Orange Book Listing
11/11/2022
 
 
TXT Imfinzi/Imjudo OK’d for Lung Cancer
11/11/2022
 
 
TXT ‘Device’ Definition Guidance
11/10/2022
 
 
TXT ICH Guide on Cell-line Product Viral Safety
11/10/2022
 
 
TXT Expedited Program Quality Assessment MAPP
11/10/2022
 
 
TXT Change Ethical Issues for Kids’ Products: AdvaMed
11/10/2022
 
 
TXT 2 Comments on Computer Software Assurance Guidance
11/10/2022
 
 
TXT FDA Refuses to File NurOwn BLA
11/10/2022
 
 
TXT Strengthen AI Product Approval: Researchers
11/10/2022
 
 
TXT 18 Observations on Lupin FDA-483
11/09/2022
 
 
TXT ImprimisRx NJ FDA-483 Has 9 Observations
11/09/2022
 
 
TXT Reject FDA Privilege Claim in FOIA Case: WLF
11/09/2022
 
 
TXT RapidAI’s Lastest Version of Rapid ICH Cleared
11/09/2022
 
 
TXT Insulet Diabetes Manager Correction
11/09/2022
 
 
TXT Panel Backs AstraZeneca Asthma Product in Adults
11/09/2022
 
 
TXT ZoomRx Keys to Better Oncology Promo Messaging
11/09/2022
 
 
<< Prev  10 11 12 13 14 15 16 17 18 19 20 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving